Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
DICE Therapeutics, Inc. (DICE) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/21/2023 15-12G Form 15-12G - Securities registration termination [Section 12(g)]:
08/11/2023 EFFECT Form EFFECT - Notice of Effectiveness:
08/09/2023 4 RA CAPITAL MANAGEMENT, L.P. (Former 10% owners and Director) has filed a Form 4 on DICE Therapeutics, Inc.
Txns: Unknown transaction of 7,070,205 shares @ $0
Unknown transaction of 786,407 shares @ $0
Disposed/sold 21,250 options to buy @ $14.98, valued at $318.3k
08/09/2023 SC 13D/A RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in DICE THERAPEUTICS, INC.
08/09/2023 4 TETLOW SHARON (Director) has filed a Form 4 on DICE Therapeutics, Inc.
Txns: Disposed/sold 49,841 shares @ $0
Disposed/sold 12,096 options to buy @ $17, valued at $205.6k
Disposed/sold 8,261 options to buy @ $17, valued at $140.4k
Disposed/sold 13,800 options to buy @ $17, valued at $234.6k
Disposed/sold 21,250 options to buy @ $14.98, valued at $318.3k
08/09/2023 4 Simson Jake (Director) has filed a Form 4 on DICE Therapeutics, Inc.
Txns: Disposed/sold 21,250 options to buy @ $14.98, valued at $318.3k
08/09/2023 4 Scopa James Paul (Director) has filed a Form 4 on DICE Therapeutics, Inc.
Txns: Disposed/sold 15,199 shares @ $0
Disposed/sold 25,722 shares @ $0
Disposed/sold 12,096 options to buy @ $17, valued at $205.6k
Disposed/sold 8,261 options to buy @ $17, valued at $140.4k
Disposed/sold 13,800 options to buy @ $17, valued at $234.6k
Disposed/sold 21,250 options to buy @ $14.98, valued at $318.3k
08/09/2023 4 Robertson Scott M. (CFO & CBO) has filed a Form 4 on DICE Therapeutics, Inc.
Txns: Disposed/sold 198,000 shares @ $0
Disposed/sold 7,191 options to buy @ $17, valued at $122.2k
Disposed/sold 771 options to buy @ $17, valued at $13.1k
Disposed/sold 20,751 options to buy @ $17, valued at $352.8k
Disposed/sold 2,688 options to buy @ $17, valued at $45.7k
Disposed/sold 9,095 options to buy @ $17, valued at $154.6k
Disposed/sold 16,595 options to buy @ $17, valued at $282.1k
Disposed/sold 15,000 options to buy @ $17, valued at $255k
Disposed/sold 56,920 options to buy @ $17, valued at $967.6k
Disposed/sold 154,250 options to buy @ $19.64, valued at $3M
Disposed/sold 112,500 options to buy @ $32.31, valued at $3.6M
08/09/2023 4 SCHELLER RICHARD H (Director) has filed a Form 4 on DICE Therapeutics, Inc.
Txns: Disposed/sold 8,427 shares @ $0
Disposed/sold 4,357 options to buy @ $17, valued at $74.1k
Disposed/sold 9,138 options to buy @ $17, valued at $155.3k
Disposed/sold 8,261 options to buy @ $17, valued at $140.4k
Disposed/sold 22,600 options to buy @ $17, valued at $384.2k
Disposed/sold 31,250 options to buy @ $14.98, valued at $468.1k
08/09/2023 4 Timothy Lu (CMO) has filed a Form 4 on DICE Therapeutics, Inc.
Txns: Disposed/sold 152,285 shares @ $0
Disposed/sold 31,304 options to buy @ $17, valued at $532.2k
Disposed/sold 25,593 options to buy @ $17, valued at $435.1k
Disposed/sold 43,167 options to buy @ $17, valued at $733.8k
Disposed/sold 157,756 options to buy @ $19.64, valued at $3.1M
Disposed/sold 90,000 options to buy @ $32.31, valued at $2.9M
Disposed/sold 15,000 restricted stock units @ $0
08/09/2023 4 Judice Kevin (CEO) has filed a Form 4 on DICE Therapeutics, Inc.
Txns: Disposed/sold 799,685 shares @ $0
Disposed/sold 20,464 options to buy @ $17, valued at $347.9k
Disposed/sold 16,661 options to buy @ $17, valued at $283.2k
Disposed/sold 131,027 options to buy @ $17, valued at $2.2M
Disposed/sold 132,074 options to buy @ $17, valued at $2.2M
Disposed/sold 384,900 options to buy @ $19.64, valued at $7.6M
Disposed/sold 300,000 options to buy @ $32.31, valued at $9.7M
Disposed/sold 50,000 restricted stock units @ $0
08/09/2023 4 Jacobsen John R. (CSO) has filed a Form 4 on DICE Therapeutics, Inc.
Txns: Disposed/sold 147,497 shares @ $0
Disposed/sold 4,367 options to buy @ $17, valued at $74.2k
Disposed/sold 922 options to buy @ $17, valued at $15.7k
Disposed/sold 1,278 options to buy @ $17, valued at $21.7k
Disposed/sold 4,229 options to buy @ $17, valued at $71.9k
Disposed/sold 1,344 options to buy @ $17, valued at $22.8k
Disposed/sold 4,408 options to buy @ $17, valued at $74.9k
Disposed/sold 14,341 options to buy @ $17, valued at $243.8k
Disposed/sold 7,579 options to buy @ $17, valued at $128.8k
Disposed/sold 11,064 options to buy @ $17, valued at $188.1k
Disposed/sold 46,324 options to buy @ $17, valued at $787.5k
08/09/2023 4 Doyle Mittie (Director) has filed a Form 4 on DICE Therapeutics, Inc.
Txns: Disposed/sold 42,500 options to buy @ $19.13, valued at $813k
08/09/2023 4 Bowers Lisa (Director) has filed a Form 4 on DICE Therapeutics, Inc.
Txns: Disposed/sold 42,500 options to buy @ $19.13, valued at $813k
08/09/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
08/09/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
08/09/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
08/09/2023 POSASR Form POSASR - Post-effective Amendment to an automatic shelf registration statement:
08/09/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
08/09/2023 8-K Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa...
Docs: "Agreement and Plan of Merger by and among DICE Therapeutics, Inc., Eli Lilly and Company and Durning Acquisition Corporation, (incorporated by reference to Exhibit 2.1 to DICE Therapeutics Inc.’s Current Report on Form 8-K filed with the SEC on June 20, 2023).",
"Amended and Restated Certificate of Incorporation of DICE Therapeutics, Inc. *",
"Amended and Restated Bylaws of DICE Therapeutics, Inc. *"
08/09/2023 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
08/09/2023 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
08/09/2023 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 4 Scopa James Paul (Director) has filed a Form 4 on DICE Therapeutics, Inc.
Txns: Gifted 220 shares @ $0
Gifted 2,200 shares @ $0
07/25/2023 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
07/25/2023 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
07/19/2023 4 Scopa James Paul (Director) has filed a Form 4 on DICE Therapeutics, Inc.
Txns: Gifted 2,200 shares @ $0
07/17/2023 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
07/17/2023 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
07/13/2023 4 Scopa James Paul (Director) has filed a Form 4 on DICE Therapeutics, Inc.
Txns: Gifted 300 shares @ $0
07/10/2023 SC 13G/A FMR LLC reports a 4.7% stake in DICE THERAPEUTICS INC
06/30/2023 SC 14D9 Form SC 14D9 - Solicitation, recommendation statements:
06/30/2023 SC TO-T Form SC TO-T - Tender offer statement by Third Party:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy